AGC Biologics A/S: Financial statements 2023
CVR: 25950941
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 2,092,565,000 and a net result of DKK 243,869,000 compared with DKK 598,949,000 the year before. That is a decrease of 16.9% compared with the year before. The profit margin was 11.7%. Equity in the 2023 report amounted to DKK 307,426,000. The solvency ratio was 8.5%. The company had 956 employees in the financial year.
- Revenue
- DKK 2,092,565,000
- Gross Profit
- DKK 501,294,000
- Profit/Loss
- DKK 243,869,000
- Equity
- DKK 307,426,000
- Total Assets
- DKK 3,623,676,000
- Employees
- 956
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 2.1B | 501.3M | 243.9M | 307.4M | 956 |
| 2022 | 2.5B | 937M | 598.9M | 661.3M | 894 |
| 2021 | 2.2B | 831.9M | 571.7M | 633.6M | 730 |
| 2020 | 1.5B | 452M | 278.5M | 339.7M | 441 |
| 2019 | 996.1M | 257.1M | 154.3M | 215.1M | 377 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
AGC Biologics A/S has published its annual report for 2022. Revenue came to DKK 2,517,996,000, and the net result was DKK 598,949,000.
About AGC Biologics A/S
AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.
